Document is current
Any future updates will be listed below
-
Authors
Anselmino, Nicolas https://orcid.org/0000-0002-6482-2623
Sanchis, Pablo https://orcid.org/0000-0002-0243-8036
Bizzotto, Juan https://orcid.org/0000-0002-7844-2162
Labanca, Estefania
Dong, Jiabin
Shepherd, Peter D. A.
Yang, Jun
Vazquez, Elba S.
Mateo, Joaquin
Gueron, Geraldine
Logothetis, Christopher J. https://orcid.org/0000-0002-6365-1711
- License Information
-
More Information
Article History
Received: 11 September 2025
Revised: 12 February 2026
Accepted: 17 March 2026
First Online: 14 April 2026
Competing interests
: The authors declare no competing interests.
: The study used established human cell lines from qualified repositories. All practices involving animals were approved by the Institutional Animal Care and Use Committee of The University of Texas MD Anderson Cancer Center (MDACC), under the regulation of the Animal Welfare Committee and conform to the NIH Policy on Human Care and Use of Laboratory Animals (protocol: #00001091-RN03). The PDX models used in this study were generated by the MDA PCa PDX Program (pcapdxprogram@mdanderson.org) from prostate cancer tissue obtained during therapeutic or diagnostic procedures, including radical prostatectomies, orthopedic and neurosurgical interventions performed to palliate complications, and biopsies of metastatic lesions. Written informed consent was obtained from patients before sample acquisition, and all samples were processed according to a protocol approved by the Institutional Review Board of the University of Texas MD Anderson Cancer Center.
